TSE:VPH Valeo Pharma (VPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesBuy This Stock About Valeo Pharma Stock (TSE:VPH) 30 days 90 days 365 days Advanced Chart Get Valeo Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day RangeC$0.05▼C$0.0852-Week Range N/AVolume51,000 shsAverage Volume59,093 shsMarket CapitalizationC$4.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewValeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.Read More… Receive VPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valeo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VPH Stock News HeadlinesValeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.February 6, 2025 | finance.yahoo.comValeo: Weak Auto Markets And EV Uncertainties Continue To Hit HardOctober 31, 2024 | seekingalpha.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 1, 2025 | Crypto 101 Media (Ad)Valeo Pharma Inc.: Valeo Pharma Reports Third Quarter 2024 RevenuesOctober 5, 2024 | finanznachrichten.deCanadian Investment Regulatory Organization Trading Halt - VPHOctober 2, 2024 | finance.yahoo.comVALEO PHARMA INITIATES RESTRUCTURING PROCEEDINGS UNDER THE CCAA TO IMPLEMENT A REVIEW OF ITS STRATEGIC ALTERNATIVESOctober 2, 2024 | finance.yahoo.comVALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUESSeptember 13, 2024 | finance.yahoo.comVALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCASTSeptember 9, 2024 | ca.finance.yahoo.comSee More Headlines VPH Stock Analysis - Frequently Asked Questions How do I buy shares of Valeo Pharma? Shares of VPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Valeo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Valeo Pharma investors own include Fission Uranium (FCU), Pasithea Therapeutics (KTTA), Pure Gold Mining (PGM), Quarterhill (QTRH), Skye Bioscience (SKYE), Skye Bioscience (SKYE) and Wave Life Sciences (WVE). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:VPH CIKN/A Webwww.valeopharma.com Phone514-694-0150FaxN/AEmployees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$32.12 million Net Margins-60.18% Pretax MarginN/A Return on EquityN/A Return on Assets-26.07% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick RatioN/A Sales & Book Value Annual SalesC$53.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.64) per share Price / BookN/AMiscellaneous Outstanding Shares98,660,000Free FloatN/AMarket CapC$4.44 million OptionableNot Optionable Beta2.32 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (TSE:VPH) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valeo Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Valeo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.